These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 8658104)
21. Positive findings for negative symptoms of schizophrenia: no longer untreatable? Stahl SM Acta Psychiatr Scand; 2006 Nov; 114(5):301-2. PubMed ID: 17022789 [No Abstract] [Full Text] [Related]
22. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779 [TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapy of schizophrenia: a review. Sigmundson HK Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S70-5. PubMed ID: 7533053 [TBL] [Abstract][Full Text] [Related]
24. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772 [TBL] [Abstract][Full Text] [Related]
25. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Sanyal S; Van Tol HH J Psychiatr Res; 1997; 31(2):219-32. PubMed ID: 9278187 [TBL] [Abstract][Full Text] [Related]
26. Risperidone in treatment-refractory schizophrenia. Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947 [TBL] [Abstract][Full Text] [Related]
27. Risperidone: an analysis of the first three years in general use. Gutierrez-Esteinou R; Grebb JA Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S3-10. PubMed ID: 9352340 [TBL] [Abstract][Full Text] [Related]
28. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone. Janssen PA; Awouters FH Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873 [TBL] [Abstract][Full Text] [Related]
29. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
30. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Stahl SM; Shayegan DK J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084 [TBL] [Abstract][Full Text] [Related]
31. Novel pharmacological approaches to the treatment of schizophrenia. Fink-Jensen A Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983 [TBL] [Abstract][Full Text] [Related]
32. The science of antipsychotics: mechanistic insight. Tamminga CA CNS Spectr; 2003 Nov; 8(11 Suppl 2):5-9. PubMed ID: 14978451 [TBL] [Abstract][Full Text] [Related]
33. Risperidone-induced tardive dyskinesia. Hong KS; Cheong SS; Woo JM; Kim E Am J Psychiatry; 1999 Aug; 156(8):1290. PubMed ID: 10450277 [No Abstract] [Full Text] [Related]
34. Recent developments in PET scan imaging of neuroreceptors in schizophrenia. Sedvall G; Pauli S; Farde L; Karlsson P; Nyberg S; Nordström AL Isr J Psychiatry Relat Sci; 1995; 32(1):22-9. PubMed ID: 7622344 [TBL] [Abstract][Full Text] [Related]
35. The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Peritogiannis V; Tsouli S J Clin Psychiatry; 2011 Jul; 72(7):1016; author reply 1016-7. PubMed ID: 21824463 [No Abstract] [Full Text] [Related]